Cadrenal Therapeutics is a clinical-stage biopharmaceutical company. It is focused on advancing the development of tecarfarin, a late-stage novel therapy with orphan drug indication for the prevention of systemic thromboembolism in patients with end-stage renal disease and atrial fibrillation.